美国FDA药品溶出方法数据库

药品通用名称	剂型	USP溶出装置	速度	溶出介质	介质体积	建议取样时间（分钟）	更新日期
Medroxyprogesterone Acetate	Tablet			Develop a dissolution method			2024/01/03
Medroxyprogesterone Acetate	Injectable Suspension			Develop a dissolution method			2023/09/15
Medroxyprogesterone Acetate (104mg/0.65ml)	Injectable Suspension			Develop a method to characterize in vitro release			2018/02/08
Mefenamic Acid	Capsule			Refer to USP			2009/12/15
Mefloquine HCl	Tablet	I (Basket)	100	SGF without enzyme	900	10, 20, 30, 45 and 60	2004/02/06
Megestrol Acetate	Oral Suspension			Develop a dissolution method			2024/01/03
Meloxicam	Capsule	I (Basket)	100	Phosphate Buffer, pH 6.1 with 0.1% Sodium Lauryl Sulfate (SLS)	500 mL (for 5 mg); 1000 mL (for 10 mg)	5, 10, 15, 20 and 30	2016/06/30
Meloxicam	Suspension	II (Paddle)	25	Phosphate buffer at pH 7.5	900	5, 10, 15 and 30	2006/01/26
Meloxicam	Tablet	II (Paddle)	75	Phosphate Buffer, pH 7.5	900	10, 20, 30, 45 and 60	2004/02/20
Meloxicam/Rizatriptan	Tablet	II (Paddle)	Mel: 75; Riz: 50	Mel: 50 mM Potassium Phosphate Buffer, pH 7.2; Riz: 50 mM Potassium Phosphate Buffer, pH 6.8	900	10, 20, 30, 45 and 60	2025/05/19
Melphalan	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Memantine HCl	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Memantine HCl	Tablet (Orally Disintegrating)	I (Basket)	100	0.1 N HCl	900	15, 30, 25 and 60	2024/11/01
Memantine HCl	Capsule (Extended Release)	I (Basket)	100	pH 1.2 NaCl/HCl Buffer (degas)	900	1, 2, 3, 4, 6, 8, 10 and 12 hours	2017/03/02
Menthol/Methyl Salicylate	Topical Patch	VI (Cylinder)	50	Neutralized phthalate buffered solution (0.2 M potassium biphthalate) with pH of 5.0 at 32 ± 0.5°C	900	10, 20, 30, 60, 120, 150 and 180	2013/01/31
Meprobamate	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Mercaptopurine	Oral Suspension	II (Paddle)	50	0.1N HCl	900	5, 10, 15, 20 and 30	2015/12/24
Mercaptopurine	Tablet	II (Paddle)	50	0.1 N HCl	900	20, 30, 45, 60, 90 and 120	2004/02/06
Mesalamine	Suppository	II (Paddle) with option to use a sinker	75 (for 500 mg) & 125 (for 1000 mg)	For 500 mg strength: 0.2 M Phosphate buffer, pH 7.5 at 37 deg. C For 1000 mg strength: 0.2 M Phosphate buffer, pH 7.5 at 40 deg. C	900	30, 60, 90, 120 and 150	2006/01/30
Mesalamine	Capsule (Delayed Release)	II (Paddle)	Phase 1 & 2: 100 rpm; Phase 3: 50 rpm	Phase 1: 0.1N HCl (degas); Phase 2: pH 6.0 Buffer (degas); Phase 3: pH 7.2 Buffer	Phase 1: 500; Phase 2: 900; Phase 3: 900	Phase 1: 120; Phase 2: 60; Phase 3: 20, 30, 45, 60, 75, 90 and 120	2016/06/30